Tabung, Fred K. http://orcid.org/0000-0001-8193-7150
Noonan, Anne
Lee, Dong Hoon
Song, Mingyang
Clinton, Steven K.
Spakowicz, Daniel
Wu, Kana
Cheng, En
Meyerhardt, Jeffrey A.
Fuchs, Charles S.
Giovannucci, Edward L.
Funding for this research was provided by:
National Institutes of Health (R00 CA207736; P30 CA016058, R03 CA197879, R21 CA222940; R21 CA230873, R00 CA 215314, U01 CA167552; U01 CA167552)
American Institute for Cancer Research
American Cancer Society (MRSG-17-220-01-NEC)
Article History
Received: 28 April 2020
Accepted: 11 August 2020
First Online: 27 August 2020
Ethics approval and consent to participate
: The study was approved by the institutional review boards of the Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required. Study participants consented by completing and submitting study questionnaires. Participants were free to terminate participation in the study at any time.
: Not applicable.
: Charles S. Fuchs reports consulting role for Agios, Bain Capital, Bayer, Celgene, Dicerna, Five Prime Therapeutics, Gilead Sciences, Eli Lilly, Entrinsic Health, Genentech, KEW, Merck, Merrimack Pharmaceuticals, Pfizer, Sanofi, Taiho, and Unum Therapeutics. He also serves as a Director for CytomX Therapeutics and owns unexercised stock options for CytomX and Entrinsic Health. All other authors declare no conflict of interest.